Abstract-Rat brain particulate fraction was found to contain binding sites for 1251-Salmon Calcitonin-I (1251-SCT). Maximum binding occurred in the physiological pH range of 7.25-7.5. The binding reaction proceeded in a temperature-dependent manner. Binding sites were broadly distributed among the various rat brain regions and considerable regional differences existed in the affinity and density as detected by Scatchard analysis. The highest affinity was recorded in the case of the hypothalamus and the lowest in the case of the cerebellum. The KD (nM) and Bmax (pmole/mg protein) estimated for the binding to four regions were as follows: hypothalamus: 1.4 and 0.19, midbrain, hippocampus plus striatum: 1.5 and 0.08, pons plus medulla oblongata: 3.0 and 0.15 and cerebellum: 8.3 and 0.20. Using a particulate fraction of rat brain void of cerebellum and cortices, a binding assay for calcitonins was developed. Binding of '251-SCT was inhibited by unlabeled salmon, [Asu1,']-eel** and porcine calcitonins in a dose-dependent manner and the IC50s were 2.0, 8.0 and 30 nM, respectively. The IC50s were comparable to those estimated using a kidney particulate fraction. Human calcitonin, 3-endorphin and substance P were weak inhibitors of the binding. Other peptides, drugs and putative neuro transmitters tested (totally 23 substances) failed to inhibit the binding at concentrations of 1.0 SaM. The physiological significance of brain binding sites for calcitonin, with the possiblity that the brain may possess endogenous ligands for these sites are discussed.
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In the research field of neuroendocrinology, there is a rapidly growing concept that the central nervous system shares with peripheral tissues a number of chemical messengers (1, 2) . Calcitonin is a peptide hormone con sisting of 32 amino-acid residues secreted from the C-cells of mammalian thyroid gland and in the ultimobronchial gland, in lower orders. It acts peripherally to regulate the blood calcium level (3).
Very recently we observed in a preliminary experiment that the rat brain contains high affinity binding sites for '251-salmon calcitonin -I (4) . A suggestion has been made that the binding sites might mediate some behavioral effects of centrally administered calcitonins (5) (6) (7) (8) (9) (10) . In addition, we detected in rat brain, the presence of a calcitonin-like activity, in terms of the activity to inhibit ultimobronchial calcitonin binding to the brain tissue (11) .
These are the first biochemical indications that hormones of the calcitonin family may play an unspecified but direct role(s) in brain physiology. In this paper, experimental details of the binding assay are presented and we postulate that the ligand-like property of salmon calcitonin is specific to the calcitonin family and is not shared by other putative neurotransmitters. Preparation of '25I-Salmon Calcitonin-I: Iodination was performed by the method of Marchalonis (18) . The reaction mixture contained calcitonin (5.0 nmole), Na 12'I diluted with Na 1271 (5.0 nmole as iodide, specific activity; 0.10 mCi/nmole), hydrogen peroxide (5.0 nmole), lactoperoxidase (0.025 nmole), EDTA (20 nmole) in 0.13 ml of 34 mM potassium phosphate buffer (pH 6.0). The reaction was started by the final addition of hydrogen peroxide and allowed to proceed at 25°C for 10 min. The mixture was diluted with 0.13 ml of 20 w/v % of sucrose solution and passed through a Bio-Gel P-4 column (0.9x26 cm) in 0.20 M potassium phosphate buffer (pH 6.0) containing 70 flM of bacitracin. The labeled peptide was recovered in single peak of radioactivity and specific binding activity (Fig. 1) . The peak fractions (usually three to four tubes, 0.5 ml each) were combined and the specific activity was adjusted to 0.10 Ci/gmole. Unless otherwise specified, 1251-Calcitonin refers to '251-salmon calcitonin-I. In some cases, I'll [Aus','] -eel calcitonin was similarly prepared and used as a ligand. The solution containing labeled calcitonin was rapidly frozen in dry ice acetone and kept at -20°C until used.
MATERIALS AND METHODS

Materials
Binding assay: Male adult Wistar rats (150-170 g) were decapitated, the brain and kidneys rapidly removed and chilled to 4°C. All further procedures were carried out at 4°C and all centrifuging was done at 20,000 23,000xg for 10 min. Dissection of brain into specified regions was carried out ac cording to the procedure of Glowinski and Iversen (19) . The lower part of the brain except for the cerebellum and cerebral cortex, was used for routine assays. The tissue was homogenized in 50 mM Tris-CI (pH 7.4), incubated for 30 min, then centri fuged. The pellet was washed twice with buffer and suspended in buffer by homoge nizing. Protein was estimated by the method of Lowry et al. (20) , with bovine serum albumin as a standard. Unless otherwise described, a standard assay mixture (1.0 ml) in a polyethylene test tube contained the pellet suspension (1.6 mg as protein), bacitracin (34 nmole) and 1251-Calcitonin (1.0 pmole), in 50 mM Tris-CI (pH 7.4), with or without cold salmon calcitonin (1.0 nmole). The mixture was incubated at 4°C for 30 min and centrifuged. For counting, the pellet was dispersed in 2 w/v % SDS solution by incubating at 60°C for more than 2 hr.
RESULTS
Establishment of binding assay conditions:
Binding of 125l-Calcitonin was highly de pendent on the pH of incubation mixture. The pH profile exhibited a sharp peak in physiological pH range (Fig. 2) . At this pH, the sulfide bridge of calcitonin may be labile and it is possible that the S-S interchange is involved in binding. It has been established that binding of 1251-[Asu',']-eel calcitonin displayed a similar pH profile and [Asu','] -eel calcitonin is a potent inhibitor of 125I Calcitonin binding, as described below. Thus, the probability of S-S interchange playing a significant role in binding is low. Figure 3 shows the effects of temperature on binding. At 25 or 37°C, maximum binding was attained within 2 min and thereafter the binding tended to decrease. At 4'C, binding pro ceeded more slowly, but the rate was still high and reached a maximum within 30 min.
In our assay procedure, ligand-bound particulate fraction was separated by a 10 min centrifugation. For studies on the time course of binding, this step was too lengthy. Attempting to minimize the separation time, a filtration method using a glass fiber filter (Whatmann G F/13) was tested. The filter strongly bound 1251-Calcitonin, giving a high control value. The non-specific binding was not effectively inhibited by bovine serum albumin (1%) or bacitracin (70 jiM). Thus, 30 min incubation at 4°C and pH 7.4 followed by 10 min centrifugation were employed as the standard assay conditions throughout this work.
Another problem which ensued during set up of the assay conditions was the unexpected binding of 125l-Calcitonin to the polyethylene tube itself. This binding occurred in a cold calcitonin-replacable manner. Salmon and porcine calcitonins were almost equipotent and the IC50s were relatively high around 0.1 ,uM (compared with the inhibition curves of these calcitonins in Fig. 6 ), but replacing curves had gentle slopes and replacement was detectable even in nanomolar concentrations. Bovine serum albumin (1 %) did not inhibit the non-specific binding to the tube. In contrast, bacitracin prevented the binding, in a dose dependent manner, and in concentrations over 25 jiM, the binding was negligible. Thus, addition of the antibiotic was a must for the binding assay. So far, we have not been successful in finding a more effective substitute for bacitracin. Though it is possible that bacitracin depresses not only cold calcitonin-replacable binding of 125I Calcitonin to the tube but also that to the tissue particulate fraction, henceforth, the specific binding to tissue was designated as the cold-calcitonin-replacable binding in the presence of 34 ,uM or more of bacitracin. To be noted here, is the finding that when the concentration of cold salmon calcitonin was increased from 1 to 10 ,uM in the control assay tube, there was no significant increase in the specific binding.
Binding at equilibrium and regional variation: When increasing amounts of 125I Calcitonin were incubated with particulate fraction of whole brain homogenate, the binding was found to be saturable reaction. As described previously, a Scatchard plot detected the presence of at least two types of binding sites with high (KD=0.65 nM) and low (KD=12 nM) affinities (4). Individual studies on specified regions of brain revealed however that, in general, one region had one population of binding sites in so far as judged from KD. Among the brain regions examined, the highest affinity was recorded in the case of the hypothalamus (Figs. 4 and  5) . Specific binding to cerebral cortex and cerebellum was negligible and lowest in affinity. Binding sites with intermediate affinities were located in remaining regional complexes. Table 1 compares kinetic para The specific binding gave a saturable curve ( ). Each point is the mean of two triplicate determinations and 1.0x105 cpm in the radioactivity corresponds to 1.23 fmole of 1251-Calcitonin. (Fig. 6) . The IC50 for the peptide was 2.0 nM. A derivative of eel calcitonin was also a potent inhibitor of the binding. In contrast, two mammalian calcitonins tested herein were relatively weak inhibitors. For human calcitonin which is known to be closest to rat calcitonin chemically and immunologically (21), a high concentration such as 1 ,uM was required to achieve detectable inhibition. Figure 7 compares inhibitory potencies of calcitonins on the specific binding of 1251 Calcitonin to kidney particulate fraction. The IC50s of salmon, [Asu1°']-eel and porcine hormones were 1.0, 4.5 and 17 nM, respectively. These values were comparable to those obtained above, using brain particulate fraction (Table 2) . Here also, human calcitonin was a weak inhibitor.
Of ten different peptides tested at 1.0 iiM, 8-endorphin and substance P elicited slight [Asu1°s]-oxytocin. In addition, the following substances were not inhibitory at 1.0 ziM; diazepam, imipramine, chlorpromazine, mor phine, atropine, noradrenaline, GABA, gluta mate, aspartate, proline, glycine, dopamine, serotonin, histamine and haloperidol.
DISCUSSION
Using the binding assay developed herein, we detected specific binding sites for ultimobronchial calcitonin in rat brain. Similar binding sites were also present in mouse and bovine brains (data not shown). In rat brain, the binding sites are distributed broadly but not uniformally among brain regions. The kinetic parameters of binding exhibited significant regional variation. The hypo thalamus recorded a lowest KD which was comparable to the parameter reported for some peptidergic transmitter candidates in the central nervous system (e.g. Met5 enkephalin: 1.8 and 5.8 nM (22) Insofar as examined, binding to the brain particulate fraction appears to be a specific property commonly shared by the calcitonin family of peptides. Exceptions were e9 endorphin and substance P, but as compared with the KDs estimated for their own receptors (23, 25) , higher concentrations were required to inhibit binding of 12.I-Calcitonin. Thus, the results obtained indicate that brain tissue is equipped with ultimobronchial calcitonin like-specific receptors and that these receptors act in the mediation of the behavioral effect of centrally given calcitonins, such as analgesia (5) (6) (7) (8) (9) , tremor (9) and decreased eating (10) .
However, it is considered to be less likely that all of such behavioral effects reflect the hormonal actions of calcitonin endogenously secreted from the thyroid gland, because; 1) only the anorectic effect has been evaluated by peripheral administration and 2) the IC50s of mammalian calcitonins estimated herein are relatively high while the plasma level of the hormone is fairly low, under normal conditions. According to Austen et al. (26) , in humans, the plasma levels are in a range of 0.01-0.03 nM. Thus, we speculate that the binding sites may not exist as the receptor for the thyroidal calcitonin but rather as receptors for a novel type of calcitonin-like substance which may be of brain origin. In a preliminary experiment, we observed that a calcitonin-like substance in the rat brain behaves differently from that of thyroidal calcitonin (11) .
When an acid-butanol extract of five rat brains was fractionated by gel-filtration on Sephadex G-50, the tissues were found to contain a distinct amount of calcitonin-like substance as characterized by the binding assay, and the substance appears to have a molecular weight of around 10,000. Similar activity was also detectable in the extract of thyroid glands from the same group of animals, albeit in a lesser amount. Though the chemical nature of the brain substance remains unknown, these observations suggest that brain tissue has the ability to produce a brain specific calcitonin. Very recently, calcitonin-like immunoactivity has been detected in the cells of the anterior and intermediate lobes of the rat pituitary gland (27, 28) , implying "ectopic" production of calcitonin not only by transformed cells but also by non-tranformed cells. In addition, the findings of Nakanishi et al. (29) on ACTH-(3-LPH precursor of bovine pituitary provide clear evidence for the production of the hormone by the pituitary and other tissues including brain. Despite their conclusion that the precursor does not contain any other biologically active sequences other than those of ACTH, MSHs and opioid peptides, it should be pointed out that in the N terminal half of the precursor, there is a 32 amino-acid sequence corresponding to a skeletal structure which is basic to that of calcitonins. The same consideration has been made by Margules et al. (28) who compared calcitonin-like immunoactivity in pituitaries of obese and lean rats. Thus, it will be of interest to determine whether or not the brain-born calcitonin-like substance bears any structural relationship to the N terminal half of the ACTH-8-LPH precursor.
The binding assay using brain tissue has advantages over classical receptor assay methods developed for thyroidal calcitonins (30) ; the ease of obtaining and preparing tissue sample, abundance of binding sites and, more important for assay of brain materials, the possible selectivity for ectopically produced calcitonin-like materials, which may not be accurately estimated by the classical methods. On the other hand, our assay method is disadvantageous in that we do not know yet for which function of the brain the binding sites exist. Further systematic studies on the biological sig nificance of the binding sites are underway.
